MRRs and EMRRs for women with ACS

Slides:

Advertisements

Similar presentations

Patient Oriented Therapy Non STE ACS

Advertisements

Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.

COURAGE: Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation Purpose To compare the efficacy of optimal medical therapy (OMT)

1 What is… ? Disparities Among Women in Acute Cardiac Care Frances Canet, MD Cath Conference Thursday, May 26, 2011.

VBWG CHARISMA Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance trial.

PPAR  activation Clinical evidence. Evolution of clinical evidence supporting PPAR  activation and beyond Surrogate outcomes studies Large.

Date of download: 5/28/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Long-term Risk of Mortality and End-Stage Renal Disease.

Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:

Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Making Sense of Statistics in Clinical Trial Reports:

Cardiology Division, Jeju National University Hospital, Jeju, KOREA

Reducing Adverse Outcomes after ACS in Patients with Diabetes Goals

Arch Intern Med. 2007;167(1): doi: /archinte Figure Legend:

By Saranya Temprasertrudee M.D.

Patient populations by study group figure 10

Clinical need for determination of vulnerable plaques

Ischaemic Heart Disease Acute Coronary Syndrome

Copyright © 2009 American Medical Association. All rights reserved.

Has acute myocardial infarction mortality hit rock bottom

First time a CETP inhibitor shows reduction of serious CV events

Effect of Obesity on In-Hospital Mortality in Patients with Cardiogenic Shock Complicating AMI Obesity is paradoxically associated with favorable mortality.

Oral Anticoagulation and Preventing Stent Thrombosis

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

Volume 84, Issue 2, Pages (August 2013)

Glenn N. Levine et al. JACC 2016;68:

Creatinine clearance (mL/min) n All-cause mortality (%)

Chapter 2: Pharmacological cholesterol-lowering treatment in adults

Early Invasive Versus Initial Conservative Strategies for Women with Non–ST-Elevation Acute Coronary Syndromes: A Nationwide Analysis Islam Y. Elgendy,

Prevalence of statin and beta-blocker use by clinical presentation

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Statins Evaluation in Coronary procedUres and REvascularization

European Heart Association Journal 2007 April

The Management of ACS “Updated Perspectives and Goals” Rafid F. Al-Aqeedi FIBMS ( Med ), MRCP (London), DM ( Int.Card.), FACC, FESC Consultant Interventional.

Recent Temporal Trends in the Presentation, Management, and Outcome of Women Hospitalized with Acute Coronary Syndromes Avi Sabbag, MD, Shlomi Matetzky,

Figure 2 Ischaemic and bleeding outcomes in the major clinical trials

Figure 1 PCI strategies in patients with STEMI and multivessel disease

Nat. Rev. Cardiol. doi: /nrcardio

Preventive Angioplasty in Myocardial Infarction Trial

Antiplatelet Therapy Use after Discharge among Acute Myocardial Infarction Patients with In-hospital Bleeding Tracy Y. Wang, MD, MHS, Lan Xiao, PhD, Karen.

TRIAL HIGHLIGHT FROM ESC 2016: ACUTE CORONARY SYNDROMES

Effect of PCI on 1-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval (bars);

The European Society of Cardiology Presented by RJ De Winter

P2Y12 blockade versus placebo; risk ratio with 95% CIs for the primary composite end point of cardiovascular death, non-fatal myocardial infarction and.

Figure 4 Observational studies on multiple treatment strategies

Global Registry of Acute Coronary Events: GRACE

Volume 383, Issue 9925, Pages (April 2014)

What oral antiplatelet therapy would you choose?

Early and long-term outcomes of coronary artery bypass grafting in patients with acute coronary syndrome versus stable angina pectoris Toshihiro Fukui,

Flow chart of the study population according to thienopyridines used in the FAST-MI registry in patients with STEMI and NSTEMI. FAST-MI, French Registry.

Potassium levels and risk of in-hospital arrhythmias and mortality in patients admitted with suspected acute coronary syndrome Jonas Faxén, Hong Xu,

Measure-specific reasons for exclusion (2010-Q4–2013-Q3).

Characteristics of 21,484 Patients With MI Who Survived for >30 Days After Discharge, by Calendar Year - Part I Soko Setoguchi, et al. J Am Coll Cardiol.

Adjunctive Therapies in the Treatment of Acute Coronary Syndromes

ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): a retrospective.

Associations between type of MI and incident HF

Multivariate Cox survival analysis with predictors of mortality after adjusting for comorbidities and DBT. COPD, chronic obstructive pulmonary disease;

Baseline Q Waves and Time From Symptom Onset to ST-segment Elevation Myocardial Infarction: Insights From PLATO on the Influence of Sex Naji Kholaif,

Lifetime heart failure risk*

The benefit of evolocumab treatment is consistent regardless of inflammation level HR %CI ARR 1.6% 1.8%

A model of variation and accelerating factors in the process of acute care chain of patients with STEMI going for primary PCI. PCI, percutaneous coronary.

Christian Madelaire et al. JCHF 2018;6:

Effect of PCI on 3 to 5-year risk of all-cause mortality and major cardiovascular outcomes. CABG, coronary artery bypass grafting; CI, confidence interval.

Pamela E. Scott et al. JACC 2018;71:

Figure 7. Subgroup analysis according to the study design and support of CPB during CABG. The study design and support of CPB did not affect the results.

Use of evidence-based cardiac medications before, during and after hospitalisation for the index event in (A) overall ACS population and (B) patients with.

R. Jay Widmer, MD, PhD, Peter M. Pollak, MD, Malcolm R

FFR guided deferral of PCI in patients with ACS and stable coronary artery disease (SCAD). FFR guided deferral of PCI in patients with ACS and stable coronary.

Cardiovascular Epidemiology and Epidemiological Modelling

Identification of thresholds for significant renal recovery in relation to patient and renal survival. Identification of thresholds for significant renal.

Proposed future revascularisation strategy in patients with ESRD based on our current results and previous guideline recommendations. Proposed future revascularisation.

Study flow chart and diagnosis at discharge from ED

Presentation transcript:

MRRs and EMRRs for women with ACS STEMI (N=60,712) NSTEMI (N=119,656) MRR (95% CI) EMRR (95% CI) Adjusted for age, year of hospitalization 6 months 1.01 (0.97-1.05) 2.12 (1.85-2.42)* 0.93 (0.91-0.95)* 1.14 (1.10-1.18)* 1 year 1.01 (0.95-1.05) 3.29 (2.40-4.51)* 0.93 (0.92-0.95)* 1.24 (1.19-1.29)* 5 year 1.03 (1.00-1.07) 1.91 (1.73-2.10)* 0.95 (0.92-0.97)* 1.35 (1.28-1.42)* Adjusted for age, year of hospitalization, comorbidities 1.02 (0.98–1.06) 1.65 (1.50–1.81)* 0.96 (0.94–0.99) 1.15 (1.11–1.19)* 1.01 (0.96–1.05) 1.89 (1.66–2.16) 0.97 (0.95–0.99) 1.20 (1.16–1.24)* 1.03 (0.99–1.07) 1.60 (1.48–1.72)* 1.26 (1.21–1.32)* Adjusted for age, year of hospitalization, comorbidities, treatments at discharge 0.94 (0.91–0.98)* 1.26 (1.16–1.37)* 0.88 (0.86–0.90)* 0.97 (0.94–1.00) 0.92 (0.89–0.96)* 1.43 (1.26–1.62)* 0.88 (0.87–0.90)* 1.01 (0.97–1.04) 0.93 (0.89–0.96)* 1.31 (1.19–1.43)* 0.89 (0.87–0.91)* 1.07 (1.02–1.12)* *Significance level <0.05 ACS: acute coronary syndrome; STEMI: ST-segment-elevation myocardial infarction; NSTEMI: non-ST-segment-elevation myocardial infarction; MRR: mortality rate ratio; EMRR: excess mortality rate ratio; CI: confidence interval. Comorbidities: DM, hypertension, MI, cerebrovascular diseases, peripheral vascular disease, HF Treatments at discharge: Aspirin, b-blockers, statin, ACE inhibitors or ARBs, P2Y12 inhibitors, reperfusion (fibrinolysis or primary PCI), revascularization (PCI or CABG) Alabas OA, et al. JAHA 2017;6:e007123